

Enantioselective Annulations for Dihydroquinolones by in Situ Generation of Azolium Enolates

Anna Lee, Ashkaan Younai, Christopher K. Price, Javier Izquierdo, Rama K. Mishra, and Karl A. Scheidt*

Department of Chemistry, Center for Molecular Innovation and Drug Discovery, Chemistry of Life Processes Institute, Northwestern University, Silverman Hall, Evanston, Illinois 60208, United States

Supporting Information

ABSTRACT: A convergent, catalytic asymmetric formal [4 + 2] annulation for the synthesis of dihydroquinolones has been developed. Carboxylic acids can be employed as precursors to NHC enolates through an in situ activation strategy. Simultaneous generation of a reactive aza-*o*-quinone methide under the basic conditions employed for NHC generation leads to a dual activation approach.

Dihydroquinolones are found in numerous natural products and therapeutically relevant compounds.¹ Due to the prevalence of this structural motif in bioactive compounds and approved pharmaceuticals such as cilostazol, cartelolol, and pinolinone, as well as its utility as a synthetic intermediate for the synthesis of other bioactive compounds such as tetrahydroquinolines, the development of new asymmetric methods to fashion dihydroquinolone is a high value goal.² Previous approaches for the preparation of enantioenriched quinolone derivatives mainly utilize transition metal catalysis.³ Within the area of organocatalysis, the Córdoba group reported an asymmetric synthesis of 1,2-dihydroquinolidines using chiral amine catalysts,⁴ and the Lu group reported an asymmetric synthesis of 2-aryl-2,3-dihydro-4-quinolones using bifunctional thiourea catalysts.⁵ More recently, the groups of Akiyama⁶ and Gong⁷ independently reported a selective approach for the preparation of tetrahydroquinoline derivatives using chiral phosphoric acids.⁸ However, a *convergent* and efficient asymmetric approach for the synthesis of the dihydroquinolin-2-one scaffold is currently underdeveloped, and such a transformation could facilitate access to this privileged scaffold with various substitution patterns and high levels of enantioselectivity.

Organocatalysis has emerged as a powerful strategy to construct various hetero- and carbocyclic systems. *N*-Heterocyclic carbenes (NHCs) in particular demonstrate great versatility and selectivity to facilitate many transformations, including enolate processes and nontraditional umpolung reactivity.⁹ We have been engaged in enhancing NHC reactivity and selectivity through the integration of this Lewis base catalysis mode with other strategies, including Lewis acids,^{10,11} Lewis bases such as fluoride,¹² and Brønsted acids.^{13,14} On the basis of this cooperative catalysis/activation concept, we envisioned that a “dual activation” approach could lead to the formation of dihydroquinolone derivatives. The dual activation classification would apply if a compatible Brønsted base could be leveraged to both provide NHC formation from the azolium salt precatalysts and promote in situ creation of an aza-*o*-quinone methide (aza-*o*-

QM).¹⁵ This species could behave as an electrophile with an NHC-enolate to provide the desired dihydroquinolone in a convergent process (Figure 1A). However, given the potential




Figure 1. Dual activation strategy.

high reactivity of the aza-*o*-QM, it was also entirely possible at the onset of these investigations that a nucleophilic NHC and/or base would simply undergo an unproductive addition reaction.

At the onset, cinnamaldehyde and *tert*-butyl carbamate (Boc) protected 2-aminobenzyl chloride were employed as the nucleophile and electrophile precursors, respectively (not shown). With cinnamaldehyde as the enolate progenitor, a mixture of several products was observed, with dimers formed through the enolate (not shown) and homoenolate (shown, Figure 1B) pathways predominating. This dimerization with enals as substrates for NHC-enolate or NHC-homoenolate


Received: June 11, 2014

Published: July 13, 2014


reactions continues to be a significant challenge in reaction design in the area of carbene catalysis.¹⁶ We hypothesized that carboxylic acids could be activated in situ through the appropriate reagent combinations to react with a NHC and thus generate the desired NHC-enolate/acyl azolium. Once the carboxylic acid is activated, the acylation of the NHC and subsequent enolization could form the necessary NHC enolate, thereby eliminating the possibility of dimerization observed with enals. Carboxylic acids present two advantages: (1) they are readily available and more stable compared to enals, α -aryloxy acetaldehydes,¹⁷ and α -functionalized alkyl aldehydes used previously in carbene-catalyzed enolate reactions,¹⁸ and (2) they are less prone to undergo enolate/aldol chemistry compared to ketones and activated esters. In situ activation of acids to access enolate reactivity has proven successful in organocatalysis,¹⁹ but this strategy has not seen successful implementation in carbene catalysis.²⁰ A potential complication in this context with carbene catalysis would be the direct addition of the nucleophilic C2 position of the NHC to any in situ activation reagent. Recently, the Chi group has demonstrated the ability to access NHC enolates through the acylation of carbenes with saturated highly activated aryl esters.^{21a,11b,21b} However, the use of more stable acid substrates *directly* in NHC catalysis has not been reported. Herein, we report an asymmetric annulation reaction for the synthesis of dihydroquinolone derivatives with carboxylic acids via in situ generated azolium enolates (Figure 1).²²

To test our hypothesis, we screened several acid activating reagents (isobutyl chloroformate, SOCl₂, 2,4,6-trichlorobenzoyl chloride, etc.) with hydrocinnamic acid and achiral NHC catalysts. Carbonyldiimidazole (CDI) in combination with an achiral 5,5-triazolium catalyst provided the desired dihydroquinolone in high isolated yield with minimal side products. After further screening with chiral triazolium catalysts (Table 1), we found that isobutyl-substituted catalyst **D** provided the desired product in moderate yield and enantioselectivity (entry 4). We hypothesized that the main reason for the depressed yield and enantioselectivity stemmed from decomposition of our in situ generated acyl imidazole and/or aza-*o*-quinone methide. By lowering the reaction temperature (4 °C), we were able to slightly improve both the yield and enantioselectivity (entry 5). Increasing the amount of CDI also improved the reaction yield (entry 6). The most drastic increase in yield was obtained when we added 60 mol % of imidazole, which presumably acts as a homogeneous scavenger of HCl to prevent the inactivation of our starting materials and catalyst in the reaction (entry 7). We turned our attention toward improving the enantioselectivity and screened various amino acid derived 5,5-triazolium catalysts (entries 8–16). The best results were obtained with benzyl-substituted catalyst **G** in terms of reactivity and enantioselectivity, with the desired product in 80% yield and 94:6 er (entry 10). With catalyst **H**, the desired product was obtained in slightly improved er, but decreased yield (entry 14).

With the optimized reaction conditions in hand, the scope of this formal [4 + 2] annulation was explored (Table 2). The reaction turned out to be tolerant of various starting acids. The desired dihydroquinolone derivatives were obtained in good yields (52–84%) with high enantioselectivities (up to 98:2 er) with alkyl (**3l** and **3m**), benzyl (**3a–3i**), aryl (**3j**), and heteroalkyl (**3k**) substituted acids. The products derived from meta-substituted acids (**3d** and **3e**) were obtained with slightly higher enantioselectivity; however, a noticeable electronic effect of the substituents was not observed. Gratifyingly, aliphatic carboxylic acids were suitable substrates under our reaction conditions. The

Table 1. Optimization of Asymmetric Reaction Conditions^a



entry	NHC	CDI (equiv)	solvent	% yield ^b	er ^c
1	A	1.2	CPME	no rxn	-
2	B	1.2	CPME	no rxn	-
3	C	1.2	CPME	no rxn	-
4	D	1.2	CPME	40	77:23
5 ^d	D	1.2	CPME	52	81:19
6 ^d	D	2.0	CPME	61	81:19
7 ^{d,e}	D	2.0	CPME	85	83:17
8 ^{d,e}	E	2.0	CPME	no rxn	-
9 ^{d,e}	F	2.0	CPME	no rxn	-
10 ^{d,e}	G	2.0	CPME	80	94:6
11 ^{d,e}	G	2.0	MTBE	67	94:6
12 ^{d,e}	G	2.0	THF	71	92:8
13 ^{d,e}	G	2.0	dioxane	31	88:12
14 ^{d,e}	H	2.0	CPME	47	95:5
15 ^{d,e}	I	2.0	CPME	78	82:18
16 ^{d,e}	J	2.0	CPME	75	92:8



^aConditions: **1a** (0.05 mmol, 1.0 equiv), **2a** (2.0 equiv), triazolium (0.2 equiv), Cs₂CO₃ (2.5 equiv) at 23 °C for 15 h. ^bDetermined by NMR analysis with 1,3,5-trimethoxybenzene as an internal standard. ^cDetermined by HPLC analysis. ^dReaction conducted at 4 °C. ^e60 mol % of imidazole was added.


isopropyl-substituted hydroquinolone was obtained in high yield (81%) and excellent enantioselectivity (98:2 er) by employing isovaleric acid (**3l**). Interestingly, this catalytic system could also provide high yield and enantioselectivity for acids of minimal size such as propanoic acid (**3m**). The tolerance of functionality and substitution on the aminobenzyl chloride **2** was also investigated. Both electron-withdrawing and electron-rich groups were tolerated at the C-4, C-5, and C-6 positions affording the desired products **3n–3t** in good to high yields and high enantioselectivities. However, no product was isolated when using C-3 substituted aminobenzyl chlorides because many of these potential substrates were not stable under the reaction conditions.

Two different mechanisms are hypothesized for the formation of dihydroquinolone **3** from enol **I-A** (Scheme 1): (1) a concerted [4 + 2] process and (2) a formal [4 + 2] process involving a stepwise Michael addition and annulation. The addition of catalyst **G** to acyl imidazole **1** generated in situ and subsequent formal 1,2-H migration generates NHC-enolate **I-A**. The reaction between the intermediate **I-A** and Boc-aminobenzyl chloride **2** could proceed through either a concerted [4 + 2] pathway or a stepwise NHC-acylation process. In the [4 + 2] pathway, concerted addition of in situ generated aza-*o*-quinone methide **2** and NHC enolate **I-A** via **II** (via either endo or exo transition states) could provide the desired product **3**.²³ In the Michael addition/acylation pathway, carbon–carbon bond formation through the less sterically demanding transition state

Table 2. Substrate Scope^a

^aReactions conducted on 0.3 mmol scale. Yields are of isolated product after column chromatography. Enantiomeric ratio was determined by HPLC analysis. ^bReaction conducted on 5 mmol scale. ^cAbsolute configuration was determined by X-ray crystallography.

Scheme 1. Proposed Reaction Pathway



(III) and subsequent tautomerization forms acyl azolium intermediate **IV**, which then undergoes N-acylation to afford **3** and the NHC, now free to re-enter the catalytic cycle. The current model for asymmetric induction is based on the more favored NHC-enolate conformation **I-A** versus the higher energy

possibility of **I-B** based on DFT calculations of these two rotamers (Figure 2).^{24–26}




Figure 2. DFT model for asymmetric induction.

The enantioenriched dihydroquinolone product **3a** was converted into enantioenriched tetrahydroquinoline derivative **4** and thioamide **5** to demonstrate the utility of this new transformation (Scheme 2). After removal of the Boc protecting

Scheme 2. Synthetic Transformations^a

^aReagents: (a) TFA, CH₂Cl₂; (b) Lawesson's reagent, CH₂Cl₂; (c) TFA, CH₂Cl₂; (d) LiAlH₄, AlCl₃, Et₂O/DCM

group, the resulting N–H lactam was reduced using LiAlH₄/AlCl₃ to afford the desired tetrahydroquinoline derivative (**4**), which is another important scaffold due to its bioactive properties as antihypertensives, oxytocin antagonists, vasopressin antagonists, and calcium antagonists.²⁷ The amide can also be converted into the corresponding thioamide (**5**) without racemization.²⁸ This heteroatom conversion provides a platform for further known transformations (e.g., annulations and amidine formation) to access potentially bioactive architectures.²⁹

In conclusion, the first highly efficient enantioselective NHC-catalyzed annulation reaction for the synthesis of dihydroquinolones has been developed. This transformation features a dual activation system focusing on combining a Lewis base (NHC) and in situ generated active nucleophiles and electrophiles. In addition, the utilization of unactivated carboxylic acids directly as substrates provides the desired dihydroquinolone derivatives and importantly avoids generation of dimerization side products observed when employing enals. The demonstration that activating strategies and highly reactive aza-*o*-quinone methides are compatible with nucleophilic carbene catalysis presents new opportunities to pursue in the context of asymmetric heterocyclic synthesis.

■ ASSOCIATED CONTENT

📄 Supporting Information

Experimental procedures and spectral data for new compounds, geometries, and energies of all structures discussed. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

scheidt@northwestern.edu

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support was generously provided by the NIH NIGMS (GM073072). We thank Michael Wang (NU) for assistance with X-ray crystallography.

REFERENCES

- (1) (a) Katritzky, A. R.; Rachwal, S.; Rachwal, B. *Tetrahedron* **1996**, *52*, 15031–15070. (b) Tamura, S. Y.; Goldman, E. A.; Bergum, P. W.; Semple, J. E. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2573–2578. (c) Oshiro, Y.; Sakurai, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Miwa, T.; Nishi, T. *J. Med. Chem.* **2000**, *43*, 177–189. (d) Zhao, H.; Thurkauf, A.; Braun, J.; Brodbeck, R.; Kieleyka, A. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2119–2122.
- (2) Horn, J.; Li, H. Y.; Marsden, S. P.; Nelson, A.; Shearer, R. J.; Campbell, A. J.; House, D.; Weingarten, G. G. *Tetrahedron* **2009**, *65*, 9002–9007.
- (3) For selected examples, see: (a) Shintani, R.; Yamagami, T.; Kimura, T.; Hayashi, T. *Org. Lett.* **2005**, *7*, 5317–5319. (b) Lei, B.-L.; Ding, C.-H.; Yang, X.-F.; Wan, X.-L.; Hou, X.-L. *J. Am. Chem. Soc.* **2009**, *131*, 18250–18251. (c) Szöllösi, G.; Makra, Z.; Kovács, L.; Filöp, F. *Adv. Synth. Catal.* **2013**, *355*, 1623–1629.
- (4) Sundén, H.; Rios, R.; Ibrahim, I.; Zhao, G.-L.; Eriksson, L.; Córdova, A. *Adv. Synth. Catal.* **2007**, *349*, 827–832.
- (5) Liu, X.; Lu, Y. *Org. Lett.* **2010**, *12*, 5592–5595.
- (6) Mori, K.; Ehara, K.; Kurihara, K.; Akiyama, T. *J. Am. Chem. Soc.* **2011**, *133*, 6166–6169.
- (7) Ren, L.; Lei, T.; Ye, J.-X.; Gong, L.-Z. *Angew. Chem., Int. Ed.* **2012**, *51*, 771–774.
- (8) For organocatalyzed asymmetric synthesis of 2-aryl-2,3-dihydro-4-quinolones, also see: (a) Zheng, H.; Liu, Q.; Wen, S.; Yang, H.; Luo, Y. *Tetrahedron: Asymmetry* **2013**, *24*, 875–882. (b) Kanagaraj, K.; Pitchumani, K. *J. Org. Chem.* **2013**, *78*, 744–751.
- (9) (a) Enders, D.; Niemeier, O.; Henseler, A. *Chem. Rev.* **2007**, *107*, 5606–5655. (b) Phillips, E. M.; Chan, A.; Scheidt, K. A. *Aldrichimica Acta* **2009**, *42*, 55–66. (c) Vora, H. U.; Sheeler, P.; Rovis, T. *Adv. Synth. Catal.* **2012**, *354*, 1617–1639. (d) Bugaut, X.; Glorius, F. *Chem. Soc. Rev.* **2012**, *41*, 3511–3522.
- (10) (a) Cardinal-David, B.; Raup, D. E. A.; Scheidt, K. A. *J. Am. Chem. Soc.* **2010**, *132*, 5345–5347. (b) Phillips, E. M.; Riedrich, M.; Scheidt, K. A. *J. Am. Chem. Soc.* **2010**, *132*, 13179–13181. (c) Raup, D. E. A.; Cardinal-David, B.; Holte, D.; Scheidt, K. A. *Nat. Chem.* **2010**, *2*, 766–770. (d) Cohen, D. T.; Cardinal-David, B.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2011**, *50*, 1678–1682. (e) Dugal-Tessier, J.; O'Bryan, E. A.; Schroeder, T. B. H.; Cohen, D. T.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2012**, *51*, 4963–4967.
- (11) (a) Mo, J.; Chen, X.; Chi, Y. R. *J. Am. Chem. Soc.* **2012**, *134*, 8810–8813. (b) Chen, X.; Yang, S.; Song, B.-A.; Chi, Y. R. *Angew. Chem., Int. Ed.* **2013**, *52*, 11134–11137.
- (12) Izquierdo, J.; Orue, A.; Scheidt, K. A. *J. Am. Chem. Soc.* **2013**, *135*, 10634–10637.
- (13) McCusker, E. O.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2013**, *52*, 13616–13620.
- (14) (a) Zhao, X.; Dirocco, D. A.; Rovis, T. *J. Am. Chem. Soc.* **2011**, *133*, 12466–12469. (b) Liu, G.; Wilkerson, P. D.; Toth, C. A.; Xu, H. *Org. Lett.* **2012**, *14*, 858–861. (c) Fu, Z.; Sun, H.; Chen, S.; Tiwari, B.; Li, G.; Chi, Y. R. *Chem. Commun.* **2013**, *49*, 261–263.
- (15) (a) Steinhagen, H.; Corey, E. J. *Angew. Chem., Int. Ed.* **1999**, *38*, 1928–1931. (b) Avemaria, F.; Vanderheiden, S.; Bräse, S. *Tetrahedron* **2003**, *59*, 6785–6796. (c) Yang, Q.-Q.; Xiao, C.; Lu, L.-Q.; An, J.; Tan, F.; Li, B.-J.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2012**, *51*, 9137–9140.
- (d) Yang, Q.-Q.; Wang, Q.; An, J.; Chen, J.-R.; Lu, L.-Q.; Xiao, W.-J. *Chem.—Eur. J.* **2013**, *19*, 8401–8404.
- (16) Cohen, D. T.; Cardinal-David, B.; Roberts, J. M.; Sarjeant, A. A.; Scheidt, K. A. *Org. Lett.* **2011**, *13*, 1068–1071.
- (17) (a) Kawanaka, Y.; Phillips, E. M.; Scheidt, K. A. *J. Am. Chem. Soc.* **2009**, *131*, 18028–18029. (b) Phillips, E. M.; Wadamoto, M.; Roth, H. S.; Ott, A. W.; Scheidt, K. A. *Org. Lett.* **2009**, *11*, 105–108.
- (18) (a) Reynolds, N. T.; Alaniz, J. R. d.; Rovis, T. *J. Am. Chem. Soc.* **2004**, *126*, 9518–9519. (b) Show, K. Y.-K.; Bode, J. W. *J. Am. Chem. Soc.* **2004**, *126*, 8126–8127.
- (19) For a review of this area, see: Morrill, L. C.; Smith, A. D. *Chem. Soc. Rev.* **2014**, DOI: 10.1039/C4CS00042K. For seminal and recent examples, see: (a) Cortez, G. S.; Tennyson, R. L.; Romo, D. *J. Am. Chem. Soc.* **2001**, *123*, 7945–7946. (b) Cortez, G. S.; Oh, S.-H.; Romo, D. *Synthesis* **2001**, 1731–1736. (c) Ling, K. B.; Smith, A. D. *Chem. Commun.* **2011**, 47, 373–375. (d) Belmessieri, D.; Morrill, L. C.; Simal, C.; Slawin, A. M. Z.; Smith, A. D. *J. Am. Chem. Soc.* **2011**, *133*, 2714–2720. (e) Manoni, F.; Cornaggia, C.; Murray, J.; Tallon, S.; Connon, S. J. *Chem. Commun.* **2012**, 48, 6502–6504. (f) Liu, G.; Shirley, M. E.; Romo, D. *J. Org. Chem.* **2012**, *77*, 2496–2500. (g) Taylor, J. E.; Daniels, D. S. B.; Smith, A. D. *Org. Lett.* **2013**, *15*, 6058–6061. (h) Stark, D. G.; Morrill, L. C.; Yeh, P.-P.; Slawin, A. M. Z.; O'Riordan, T. J. C.; Smith, A. D. *Angew. Chem., Int. Ed.* **2013**, *52*, 11642–11646. (i) Davies, A. T.; Taylor, J. E.; Douglas, J.; Collett, C. J.; Morrill, L. C.; Fallon, C.; Slawin, A. M. Z.; Churchill, G.; Smith, A. D. *J. Org. Chem.* **2013**, *78*, 9243–9257. (j) Smith, S. R.; Douglas, J.; Prevet, H.; Shapland, P.; Slawin, A. M. Z.; Smith, A. D. *J. Org. Chem.* **2014**, *79*, 1626–1639.
- (20) For NHC-catalyzed generation of acyl azolium species using α,β -unsaturated acid fluorides, see: (a) Ryan, S. J.; Candish, L.; Lupton, D. W. *J. Am. Chem. Soc.* **2009**, *131*, 14176–14177. (b) Ryan, S.; Candish, L.; Lupton, D. W. *Synlett* **2011**, 2275–2278. (c) Ryan, S. J.; Candish, L.; Lupton, D. W. *J. Am. Chem. Soc.* **2011**, *133*, 4694–4697. (d) Candish, L.; Forsyth, C. M.; Lupton, D. W. *Angew. Chem., Int. Ed.* **2013**, *52*, 9149–9152. (e) Candish, L.; Lupton, D. W. *J. Am. Chem. Soc.* **2013**, *135*, 58–61.
- (21) (a) Hao, L.; Du, Y.; Lv, H.; Chen, X.; Jiang, H.; Shao, Y.; Chi, Y. R. *Org. Lett.* **2012**, *14*, 2154–2157. (b) Xu, J.; Jin, Z.; Chi, Y. R. *Org. Lett.* **2013**, *15*, 5028–5031.
- (22) Douglas, J.; Churchill, G.; Smith, A. D. *Synthesis* **2012**, *44*, 2295–2309.
- (23) Ryan, S. J.; Candish, L.; Lupton, D. W. *J. Org. Chem.* **2011**, *133*, 4694–4697.
- (24) Computed with Schrödinger interface using Jaguar DFT with B3LYP/6-31G**.
- (25) For a related model of asymmetric induction with NHC-enolates invoking a rotamer similar to I-A, see: Zhao, X.; Ruhl, K. E.; Rovis, T. *Angew. Chem., Int. Ed.* **2012**, *51*, 12330–12333.
- (26) Ketene generation during this reaction is unlikely given the known methods for their preparation with strong leaving groups (e.g., acid chlorides): (a) Tidwell, T. T. *Acc. Chem. Res.* **1990**, *23*, 273–279. (b) Tidwell, T. T. *Ketenes*; John Wiley and Sons, Inc.: New York, 1995. (c) Tidwell, T. T. *Ketenes II*; John Wiley and Sons, Inc.: New York, 2006. (d) Allen, A. D.; Tidwell, T. T. *Eur. J. Org. Chem.* **2012**, 1081–1096. Additionally, we have not observed any ketene dimer products from alkanolic acid substrates (**1**, R1 = Me).
- (27) Sridharan, V.; Suryavanshi, P. A.; Menendez, J. C. *Chem. Rev.* **2011**, *111*, 7157–7259.
- (28) Koduri, N. D.; Scott, H.; Hileman, B.; Cox, J. D.; Coffin, M.; Glicksberg, L.; Hussaini, S. R. *Org. Lett.* **2012**, *14*, 440–443.
- (29) (a) Guarna, A.; Lombardi, E.; Machetti, F.; Occhiato, E. G.; Scarpi, D. *J. Org. Chem.* **2000**, *65*, 8093–8095. (b) Occhiato, E. G.; Ferrali, A.; Menchi, G.; Guarna, A.; Danza, G.; Comerci, A.; Mancina, R.; Serio, M.; Garotta, G.; Cavalli, A.; Vivo, M. D.; Recanatini, M. *J. Med. Chem.* **2004**, *47*, 3546–3560. (c) Delcrois, J.-G.; Tomasi, S.; Duhieu, S.; Foucault, M.; Martin, B.; Roch, M. L.; Eifer-Lima, V.; Renault, J.; Uriac, P. *J. Med. Chem.* **2006**, *49*, 232–245. (d) Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. *J. Med. Chem.* **2008**, *51*, 8077–8087.